文献速递甲状腺疾病

细胞学不确定甲状腺结节中RAS突变阳性预测值的异质性

Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules.
PubMed 文献 · Thyroid · 2018-05-16

该系统综述检索PubMed至2017年2月22日,纳入23项评估细胞学不确定甲状腺结节RAS突变的研究。Bethesda III、IV、V类的RAS突变阳性预测值范围分别为0-100%、28-100%、0-100%。校正Bethesda分类、病理医师盲法、各研究癌症患病率及检测的RAS基因与密码子后,残留异质性仍为中高(Bethesda III/IV/V:21项研究,I2=59.5%;Bethesda III/IV:19项研究,I2=66.0%)。作者认为Bethesda III和IV类的阳性预测值异质性大,对单一估计值信心低,临床处理RAS突变结节时须认识这种变异性。

要点

  • Bethesda III、IV、V类RAS突变阳性预测值范围分别为0-100%、28-100%、0-100%
  • 校正多种因素后残留异质性仍中高:III/IV/V类I2=59.5%,III/IV类I2=66.0%
  • 作者认为单一阳性预测值估计准确性信心低,临床须认识这种变异性

核心结论

  • Bethesda III和IV类RAS突变的阳性预测值在不同研究间高度异质,对单一阳性预测值估计的准确性信心低。
  • 临床医生在处理RAS突变的细胞学不确定甲状腺结节时须认识这种广泛变异性。
  • 未来研究应设法解释这种未明原因的变异性。

研究设计与样本

  • 系统综述,检索PubMed至2017年2月22日,纳入评估细胞学不确定结节中至少一种RAS突变且具备组织学诊断的研究,共23项符合纳入标准。
  • 采用五个Meta回归模型分别拟合Bethesda III/IV/V、III/IV、仅III、仅IV、仅V类,校正Bethesda分类、病理医师对RAS突变状态盲法、各研究Bethesda类别特异性癌症患病率及检测的RAS基因与密码子。

主要发现

  • Bethesda III类阳性预测值范围为0-100%,IV类为28-100%,V类为0-100%。
  • 校正上述调节因素后,Bethesda III/IV/V类(21项研究)残留异质性I2=59.5%,Bethesda III/IV类(19项研究)I2=66.0%,Cochran Q检验p<0.001。
  • 各Bethesda类别残留异质性:III类(8项研究)I2=89.0%,IV类(12项研究)I2=53.5%,V类(10项研究)I2=34.4%;Cochran Q检验III类p<0.001、IV类p=0.04。

关键数值与推荐

  • Bethesda III类RAS突变阳性预测值范围0-100%。
  • Bethesda IV类RAS突变阳性预测值范围28-100%。
  • Bethesda V类RAS突变阳性预测值范围0-100%。
  • 校正后残留异质性:Bethesda III/IV/V类I2=59.5%(21项研究),Bethesda III/IV类I2=66.0%(19项研究),Cochran Q检验p<0.001。
  • 各类别残留异质性:III类I2=89.0%(8项研究),IV类I2=53.5%(12项研究),V类I2=34.4%(10项研究);Cochran Q检验III类p<0.001、IV类p=0.04。

临床怎么用

  • 作者认为,临床医生在处理RAS突变的细胞学不确定甲状腺结节时须认识阳性预测值的广泛变异性。
  • 作者认为对RAS突变阳性预测值的单一估计准确性信心低。

局限性

  • 校正上述调节因素后,Bethesda III/IV/V类与III/IV类的阳性预测值残留异质性仍为中高(I2分别为59.5%和66.0%),Cochran Q检验提示残留异质性显著(p<0.001)。
  • 各Bethesda类别内残留异质性分别为III类I2=89.0%、IV类I2=53.5%、V类I2=34.4%。
  • 阳性预测值的异质性原因尚不明确,作者认为未来研究应设法解释这种未明原因的变异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RAS mutations are common in the available mutational analysis of cytologically indeterminate (Cyto-I) thyroid nodules. However, their reported positive predictive value (PPV) for cancer is widely variable. The reason for this variability is unknown, and it causes clinical management uncertainty. A systematic review was performed, evaluating the PPV for cancer in RAS mutation positive Cyto-I nodules, and variables that might affect residual heterogeneity across the different studies were considered. METHODS: PubMed was searched through February 22, 2017, including studies that evaluated at least one type of RAS mutation in Cyto-I nodules, including any (or all) of the Bethesda III/IV/V categories or their equivalents and where the histological diagnosis was available. The PPV residual heterogeneity was investigated after accounting for Bethesda classification, blindedness of the histopathologist to the RAS mutational status, Bethesda category-specific cancer prevalence for each study, and which RAS genes and codons were tested. This was studied using five meta-regression models fit to different sets of Bethesda classification categories: Bethesda III, IV, or V (III/IV/V); Bethesda III or IV (III/IV); Bethesda III only; Bethesda IV only; and Bethesda V only. RESULTS: Of 1831 studies, 23 were eligible for data inclusion. Wide ranges of PPV were found at 0-100%, 28-100%, and 0-100% in Bethesda III, IV, and V, respectively. Residual heterogeneity remained moderately high for PPV after accounting for the above moderators for Bethesda III/IV/V (21 studies; I2 = 59.5%) and Bethesda III/IV (19 studies; I2 = 66.0%), with significant Cochran's Q-test for residual heterogeneity (p < 0.001). Among individual Bethesda categories, residual heterogeneity was: Bethesda III (eight studies; I2 = 89.0%), IV (12 studies; I2 = 53.5%), and V (10 studies; I2 = 34.4%), with significant Cochran's Q-test for Bethesda III (p < 0.001) and IV (p = 0.04). CONCLUSION: The PPV of RAS mutations in Bethesda III and IV categories is quite heterogeneous across different studies, creating low confidence in the accuracy of a single estimate of PPV. Clinicians must appreciate this wide variability when managing a RAS-mutated Cyto-I nodule. Future studies should seek to resolve this unexplained variability.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Nabhan F, Porter K, Lupo MA, et al. Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules. Thyroid. 2018. PMID: 29665745. doi:10.1089/thy.2017.0635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。